Annamycin liposomal (Moleculin Biotech)
安纳霉素脂质体 (Moleculin Biotech)
Report date: 2025/11/13 16:00:03
Base Information
Drug NameAnnamycin liposomal (Moleculin Biotech)
Drug Alias Name +[8]
Classification
Mechanisms of Action
Targets
Therapy Area/Indications +[6]
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/Territory +[8]
CombinationsNo
Global Highest StatusPhase 3 Clinical
Highest Status in ChinaN/A
Originator CompaniesThe University Of Texas MD Anderson Cancer Center
China Registration ClassN/A
Develop Information
Active CompaniesMoleculin Biotech IncUniversity Of North Carolina At Chapel HillMaria Sklodowska-Curie National Research Institute of Oncology
Inactive CompaniesNational Cancer InstituteCallisto Pharmaceuticals Inc
Active Indications +[4]
Inactive Indications